Eterna Therapeutics Inc
NASDAQ:ERNA

Watchlist Manager
Eterna Therapeutics Inc Logo
Eterna Therapeutics Inc
NASDAQ:ERNA
Watchlist
Price: 1.27 USD 2.42%
Market Cap: 10m USD

Relative Value

The Relative Value of one ERNA stock under the Base Case scenario is 0.002 USD. Compared to the current market price of 1.27 USD, Eterna Therapeutics Inc is Overvalued by 100%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ERNA Relative Value
Base Case
0.002 USD
Overvaluation 100%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
3
vs Industry
29
Median 3Y
25.6
Median 5Y
20.4
Industry
7.8
vs History
vs Industry
Median 3Y
-0.4
Median 5Y
-0.5
Industry
24.1
vs History
vs Industry
Median 3Y
-0.7
Median 5Y
-0.9
Industry
21.8
vs History
vs Industry
Median 3Y
-0.9
Median 5Y
-1.2
Industry
23.8
vs History
46
vs Industry
12
Median 3Y
1.9
Median 5Y
2.5
Industry
3.3
vs History
3
vs Industry
26
Median 3Y
30.6
Median 5Y
19.1
Industry
8
vs History
3
vs Industry
22
Median 3Y
-87.6
Median 5Y
-121.1
Industry
10.3
vs History
vs Industry
Median 3Y
-0.6
Median 5Y
-0.7
Industry
6.3
vs History
vs Industry
Median 3Y
-0.6
Median 5Y
-0.7
Industry
6.7
vs History
vs Industry
Median 3Y
-0.7
Median 5Y
-0.7
Industry
7.9
vs History
vs Industry
Median 3Y
-0.7
Median 5Y
-0.7
Industry
6.3
vs History
46
vs Industry
26
Median 3Y
1.2
Median 5Y
2.7
Industry
5.5

Multiples Across Competitors

ERNA Competitors Multiples
Eterna Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Eterna Therapeutics Inc
NASDAQ:ERNA
10m USD 9 968.2 -0.5 -0.7 -0.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 675 001.5 -160 052.3 -194 354.5 -192 136.7
US
Abbvie Inc
NYSE:ABBV
406.3B USD 6.8 173 16.7 23.7
US
Amgen Inc
NASDAQ:AMGN
179.7B USD 5 25.6 18.4 18.4
US
Gilead Sciences Inc
NASDAQ:GILD
156.1B USD 5.4 19.2 12.9 12.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.6B USD 10 32 23.5 24.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 092 -533.8 -581.3 -565.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.5B USD 5.8 18 17.2 19.5
AU
CSL Ltd
ASX:CSL
83B AUD 3.6 18.5 12.5 15.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.8B USD 16.5 1 212.2 163.5 198.2
NL
argenx SE
XBRU:ARGX
44B EUR 14.4 33.8 58.2 59.8
P/E Multiple
Earnings Growth PEG
US
Eterna Therapeutics Inc
NASDAQ:ERNA
Average P/E: 191.6
Negative Multiple: -0.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 052.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
173
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.6
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19.2
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
9%
2
AU
CSL Ltd
ASX:CSL
18.5
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 212.2
N/A N/A
NL
argenx SE
XBRU:ARGX
33.8
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Eterna Therapeutics Inc
NASDAQ:ERNA
Average EV/EBITDA: 40.4
Negative Multiple: -0.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 354.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.7
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.4
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
11%
1.6
AU
CSL Ltd
ASX:CSL
12.5
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
163.5
N/A N/A
NL
argenx SE
XBRU:ARGX
58.2
807%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Eterna Therapeutics Inc
NASDAQ:ERNA
Average EV/EBIT: 46.6
Negative Multiple: -0.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 136.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.4
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.5
13%
1.5
AU
CSL Ltd
ASX:CSL
15.6
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
198.2
N/A N/A
NL
argenx SE
XBRU:ARGX
59.8
N/A N/A